Floatz logo

Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1

Hematopoietic and Lymphoid System Neoplasm

GeoVax, Inc.vaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

136 Active assets in the Hematopoietic and Lymphoid System Neoplasm cohort.

Asset / SponsorPhaseRating
Inno-206
OHSU Knight Cancer Institute
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 3BBB
Teclistamab
Janssen Pharmaceutical K.K.
Phase 2BB
DEXAMETHASONE
City of Hope Medical Center
Phase 3BB
Bortezomib
OHSU Knight Cancer Institute
Phase 4BB

View all 50 →

Same molecule, other indications

Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1 is also rated in:

COVID-19Dormant
CCC
Indicative ·
53 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
53 / 100
View asset →
leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →